Palvella Therapeutics (PVLA) vs Zenas BioPharma (ZBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Palvella Therapeutics (PVLA) has outperformed Zenas BioPharma (ZBIO) over the past year, gaining 75.5% versus a gain of 1.3%. Palvella Therapeutics is the larger company by market cap ($1.89 billion vs $1.71 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PVLA | ZBIO |
|---|---|---|
| Share price | $131.34 | $26.24 |
| Market cap | $1.89B | $1.71B |
| 1-day change | +0.57% | -6.88% |
| YTD return | +25.48% | -27.73% |
| 1-year return | +75.47% | +1.31% |
| 5-year return | -63.60% | — |
| EPS (TTM) | $-4.85 | $-9.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $10.00M |
| Revenue growth (YoY) | — | +100.00% |
| Net income (latest FY) | $-41.72M | $-377.74M |
| Operating margin | — | -3830.57% |
| Net margin | — | -3777.37% |
| 52-week high | $161.38 | $44.60 |
| 52-week low | $65.93 | $13.50 |
| Distance from 52-week high | -18.61% | -41.17% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +75.52% | +82.47% |
| Average volume | 211.36K | 735.12K |
| Shares outstanding | 14.41M | 65.18M |
| Employees | 29 | 167 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PVLA has outperformed ZBIO by 74.2 percentage points over the past year.
About Palvella Therapeutics
PVLA stock →Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Zenas BioPharma
ZBIO stock →Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Health Care · Biotechnology: Pharmaceutical Preparations · 167 employees
PVLA vs ZBIO FAQ
Which is bigger, Palvella Therapeutics or Zenas BioPharma?
Palvella Therapeutics (PVLA) is larger, with a market capitalization of $1.89B compared with $1.71B for Zenas BioPharma (ZBIO).
Which stock has performed better over the past year, PVLA or ZBIO?
PVLA returned +75.47% over the past 12 months, compared with +1.31% for ZBIO (price return, excluding dividends). Past performance does not predict future results.
Are Palvella Therapeutics and Zenas BioPharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.